.Nature Medication, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) therapy of patients with HER2+ state-of-the-art bosom cancer as well as energetic or stable mind metastases revealed constant intracranial task as well as wide spread efficacy of T-DXd.